2022 ), Jonathan brings valuable insights on internal and external relationships to our conversation .
A common goal
Returning to the business itself , although it produces pharmaceuticals for a vast range of medical conditions , the acquisition of EUSA has accelerated the group ’ s focus on rare diseases . “ The backing of a global pharmaceutical company with an established reputation like Recordati ’ s is hugely exciting for everyone at EUSA ,” recalls Jonathan . “ It gave us increased stability , and an ability to invest in our products and expand into new global markets .
“ Recordati has accepted and welcomed EUSA on board , with our teams and management smoothly adapting to new structures ,” he continues . “ I believe that we have added value to the Recordati family , and we are all pulling together to achieve our common goal – to continually improve our products to best serve our patients .”
“ I strongly agree ,” replies Roberto . “ The former EUSA has a high level of competence and experience that we didn ’ t want to lose through the acquisition process . The combination
The acquisition of EUSA has incorporated its expertise on rare conditions and oncology into Recordati ’ s reputable portfolio
of different experiences and professional pathways contributes to a better result compared to what the two companies would have achieved independently .”
Nowhere is this fusion of resources more valuable than in producing pharmaceuticals for rare diseases . The acquisition of EUSA has incorporated its expertise on rare conditions and oncology into Recordati ’ s reputable portfolio . Defined as a condition affecting fewer than five individuals per 10,000 people in Europe , or fewer than 200,000 Americans in the US , rare diseases are typically under-researched .
160